NCT06855069: An ongoing trial by Hansoh BioMedical R&D Company
This trial is ongoing. It must report results 1 year, 4 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06855069 |
|---|---|
| Title | A Multi-center, Randomized, Open-label, Controlled, Phase III Clinical Study Evaluating HS-20089 vs. Investigator's Choice of Chemotherapy in the Treatment of Platinum-resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | March 13, 2025 |
| Completion date | March 7, 2027 |
| Required reporting date | March 6, 2028, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Oct. 21, 2026 |
| Days late | None |